Eli Lilly and Company

$39.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: LLY-1 Category:

Description

Eli Lilly may have had a rough quarter after being unable to meet Wall Street expectations but the company’s stock price soared after its donanemab treatment for Alzheimer’s disease recently earned a Breakthrough Therapy designation from the U.S. FDA after its success in the Phase 2 clinical trial. If it succeeds, donanemab could give Eli Lilly an entry into the vast blue ocean market of Alzheimer’s Disease. The other promising drug candidate of the company is tirzepatide, a diabetes and obesity drug currently undergoing Phase 3 clinical trials. Eli Lilly’s current diabetes drug, Trulicity has been showing a fantastic performance and saw its revenues jump by 18% in the last quarter. Overall, the company is on track for a fantastic year ahead.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!

Menu